

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Tong Ren Tang Technologies Co. Ltd.**  
**北京同仁堂科技發展股份有限公司**

*( a joint stock limited company incorporated in the People's Republic of China with limited liability )*  
(Stock Code: 1666)

**ANNOUNCEMENT ON RESULTS OF SUBSIDIARY**

Reference is made to the announcement (the “**Announcement**”) dated 11 March 2021 and published by Beijing Tong Ren Tang Chinese Medicine Company Limited (“**Tong Ren Tang Chinese Medicine**”), a subsidiary of Tong Ren Tang Technologies Co. Ltd. (the “**Company**”) and whose shares are listed on the Main Board of The Stock Exchange of Hong Kong Limited (stock code: 3613), in relation to the annual results of Tong Ren Tang Chinese Medicine and its subsidiaries for the year ended 31 December 2020.

This announcement is made pursuant to Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) and Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

The board of directors of the Company would like to draw the attention of its shareholders and the public investors to the following audited financial information of Tong Ren Tang Chinese Medicine and its subsidiaries for the year ended 31 December 2020 as set out in the Announcement.

## CONSOLIDATED INCOME STATEMENT

	Year ended 31 December	
	2020	2019
	HK\$'000	HK\$'000
Revenue	1,315,346	1,432,632
Cost of sales	(362,443)	(419,836)
<b>Gross profit</b>	<u>952,903</u>	<u>1,012,796</u>
Distribution and selling expenses	(168,917)	(199,097)
General and administrative expenses	(138,861)	(164,824)
Other gains, net	24,278	3,111
<b>Operating profit</b>	<u>669,403</u>	<u>651,986</u>
Finance income	21,652	43,415
Finance costs	(4,300)	(4,207)
Finance income, net	17,352	39,208
Share of losses of investments accounted for using the equity method	(860)	(1,972)
<b>Profit before income tax</b>	<u>685,895</u>	<u>689,222</u>
Income tax expense	(118,014)	(112,370)
<b>Profit for the year</b>	<u><u>567,881</u></u>	<u><u>576,852</u></u>
<b>Profit attributable to:</b>		
Owners of the Company	542,456	556,118
Non-controlling interests	25,425	20,734
	<u><u>567,881</u></u>	<u><u>576,852</u></u>
<b>Earnings per share attributable to owners of the Company for the year</b> (expressed in HK\$ per share)		
<b>Basic and diluted earnings per share</b>	<u><u>0.65</u></u>	<u><u>0.66</u></u>

## CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

	<b>Year ended 31 December</b>	
	<b>2020</b>	<b>2019</b>
	<b>HK\$'000</b>	<b>HK\$'000</b>
<b>Profit for the year</b>	<b>567,881</b>	576,852
<b>Other comprehensive income/(losses):</b>		
<i>Items that may be reclassified to profit or loss</i>		
Currency translation differences	<b>15,474</b>	(1,469)
Release of exchange reserve upon liquidation of a joint venture	-	(961)
<i>Item that will not be reclassified to profit or loss</i>		
Change in fair value of financial asset at fair value through other comprehensive income	<b>(4,875)</b>	(4,485)
	<hr/>	<hr/>
<b>Other comprehensive income/(losses) for the year</b>	<b>10,599</b>	(6,915)
	<hr/>	<hr/>
<b>Total comprehensive income for the year</b>	<b>578,480</b>	569,937
	<hr/> <hr/>	<hr/> <hr/>
<b>Attributable to:</b>		
Owners of the Company	<b>550,521</b>	549,119
Non-controlling interests	<b>27,959</b>	20,818
	<hr/>	<hr/>
<b>Total comprehensive income for the year</b>	<b>578,480</b>	569,937
	<hr/> <hr/>	<hr/> <hr/>

## CONSOLIDATED BALANCE SHEET

	As at 31 December	
	2020	2019
	HK\$'000	HK\$'000
<b>Assets</b>		
<b>Non-current assets</b>		
Property, plant and equipment	187,379	194,869
Right-of-use assets	194,442	195,057
Intangible assets	54,836	60,669
Investments accounted for using the equity method	17,763	18,544
Financial asset at fair value through other comprehensive income	6,108	10,983
Deposits paid for purchase of property, plant and equipment	10,430	5,447
Deferred income tax assets, net	13,064	8,937
	<u>484,022</u>	<u>494,506</u>
<b>Current assets</b>		
Inventories	495,378	318,187
Trade receivables and other current assets	590,432	357,262
Short-term bank deposits	421,097	911,655
Cash and cash equivalents	1,426,040	1,056,711
	<u>2,932,947</u>	<u>2,643,815</u>
<b>Total assets</b>	<u><u>3,416,969</u></u>	<u><u>3,138,321</u></u>
<b>Equity and liabilities</b>		
<b>Equity attributable to owners of the Company</b>		
Share capital	938,789	938,789
Reserves		
- Other reserves	(18,917)	(26,982)
- Retained earnings	2,097,617	1,747,694
	<u>3,017,489</u>	<u>2,659,501</u>
<b>Non-controlling interests</b>	<u>112,021</u>	<u>106,135</u>
<b>Total equity</b>	<u><u>3,129,510</u></u>	<u><u>2,765,636</u></u>

## CONSOLIDATED BALANCE SHEET (CONTINUED)

	As at 31 December	
	2020	2019
	HK\$'000	HK\$'000
<b>Liabilities</b>		
<b>Non-current liabilities</b>		
Borrowings	2,052	833
Lease liabilities	63,095	59,395
Deferred income tax liabilities, net	5,696	5,376
	<hr/>	<hr/>
	70,843	65,604
	<hr/>	<hr/>
<b>Current liabilities</b>		
Borrowings	260	220
Trade and other payables	140,138	142,832
Lease liabilities	40,603	39,427
Current income tax liabilities	35,615	124,602
	<hr/>	<hr/>
	216,616	307,081
	<hr/>	<hr/>
<b>Total liabilities</b>	287,459	372,685
	<hr/>	<hr/>
<b>Total equity and liabilities</b>	<b>3,416,969</b>	<b>3,138,321</b>
	<hr/> <hr/>	<hr/> <hr/>

By order of the Board

**Tong Ren Tang Technologies Co. Ltd.**

**Gu Hai Ou**

*Chairman of the Board*

Beijing, the PRC

11 March 2021

*As at the date of this announcement, the Board comprises Mr. Gu Hai Ou, Mr. Jin Tao, Mr. Ma Guan Yu, Ms. Wu Qian, Mr. Wang Yu Wei and Ms. Fang Jia Zhi as executive Directors; Mr. Ting Leung Huel, Stephen, Ms. Chan Ching Har, Eliza and Mr. Zhan Yuan Jing as independent non-executive Directors.*